Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
Birmingham, AlabamaAges 16 years+ - NCT04866641RecruitingPhase 1
Early safety study of T-1201 for advanced solid tumors
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
Kaohsiung CityAges 20 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT04781322RecruitingPhase 1
Study drug to reduce LDL cholesterol effects in heavy drinkers
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Bethesda, MarylandAges 21–65 - NCT04786262RecruitingPhase 3
A study of VX-880 and VX-017 for type 1 diabetes
This study tests two investigational drugs, VX-880 and VX-017, for people with type 1 diabetes who have trouble controlling their blood sugar and have frequent severe low blood sugar episodes. The goal is to see if these drugs can improve blood sugar control and reduce dangerous lows.
Duarte, CaliforniaAges 18–65 - NCT04848506Enrolling by invitationPhase 2/Phase 3
Long-term safety follow-up with aficamten for adults with HCM
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
Birmingham, AlabamaAges 18–85 - NCT04731272RecruitingPhase 2
Weekly GLP-1 medicine for blood sugar issues in adults with CF
This Phase 2 trial tests a weekly GLP-1 medicine (dulaglutide) to improve blood sugar control in adults with cystic fibrosis (CF) who have trouble managing glucose. It may help people with CF-related prediabetes or diabetes by improving how their body handles sugar.
Aurora, ColoradoAges 18 years+ - NCT04715646RecruitingPhase 3
Brivaracetam study for children with hard-to-control seizures
This trial looks at how safe brivaracetam is and how well it can be used in children and teens with certain types of epilepsy that are not well controlled. It may help families who are dealing with frequent focal seizures despite taking seizure medicines.
Hawthorne, New YorkAges 1 month+ - NCT04581512RecruitingPhase 1/Phase 2
Safety study of EP0042 for certain AML patients
This Phase 1/2 study tests how safe and tolerable EP0042 is, and looks at patients with a specific type of AML that has come back or did not respond to prior treatment. You may be considered if your AML diagnosis is confirmed and your lab tests, overall health, and medication history fit the study rules.
Perth, Western AustraliaAges 18 years+ - NCT04571203RecruitingPhase 1
Kidney transplant plus blood-cell treatment to help the graft settle
This Phase 1 study tests a treatment plan (including rabbit medicine and a low dose of radiation) meant to help the new kidney “take” and work longer. It also includes a kidney-from-deceased-donor process and checks how safely the treatment works in people with end-stage kidney disease.
Palo Alto, CaliforniaAges 18–65 - NCT04425395Recruiting
Sounds without words may change pain tolerance
This study looks at whether nonverbal vocal sounds (like certain tones or sounds) change how much pain you can tolerate. You might be asked to listen to or produce sounds while your pain response is measured.
Saint-EtienneAges 18–60 - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04456816RecruitingPhase 2
Drug test for IgA? No—anti-PLA2R positive immune kidney disease
This Phase 2 trial studies AP1189 in people with a specific immune-related kidney disease called iMN and very high urine protein. It aims to see whether the drug is safe and tolerable and if it can reduce protein in the urine.
AarhusAges 18–85 - NCT04358146Recruiting
Test a new formula to reduce infant spit-up
This study tests whether a new anti-regurgitation infant formula can reduce how often your baby spits up, and whether babies tolerate it well. It may help families who are feeding with formula and seeing frequent regurgitation (spit-up).
NamurAges 2 weeks–4 months - NCT04300556RecruitingPhase 1/Phase 2
Testing an antibody-drug for advanced certain cancers
This early-phase trial tests a treatment called MORAb-202, an antibody “delivery” drug, to see if it’s safe and can help shrink or control certain advanced cancers. It may help people whose tumors match the study’s specific cancer types and prior treatment history.
Tucson, ArizonaAges 18 years+ - NCT04271878Recruiting
Test breathing and blood-pressure response in POTS patients
This study measures how breathing patterns and heart rate/blood pressure change when you move from lying to standing in people with POTS. It may help researchers understand symptoms better and improve ways to manage them.
Calgary, AlbertaAges 18–60 - NCT04216342RecruitingPhase 1
Testing a new breathing-drug ingredient in healthy adults
This early study (Phase 1) tests how safe and tolerable Fx-5A is, and how the body processes it, in healthy volunteers. It’s mainly looking to understand side effects and drug levels rather than treating a disease.
Bethesda, MarylandAges 18–99 - NCT04165486RecruitingPhase 1
Test drug safety in adults with multiple system atrophy
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
InnsbruckAges 40–70 - NCT04192344RecruitingPhase 1
First test of an anti-cancer drug for advanced solid tumors
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
Beverly Hills, CaliforniaAges 18 years+ - NCT03373968RecruitingPhase 2/Phase 3
Long-term study of givinostat safety in Duchenne muscular dystrophy
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
Sacramento, CaliforniaAges 7 years+ - NCT04055428RecruitingPhase 2
Testing a hormone supplement to improve heart and metabolic health
This study tests whether adding a natriuretic peptide medicine improves heart health and metabolism in Black adults. It may help with blood pressure and related health markers, but you must meet specific health and safety criteria.
Birmingham, AlabamaAges 18 years+ - NCT03955445RecruitingPhase 3
Study for long-term iptacopan in C3G or IC-MPGN
This Phase 3 trial looks at how well and how safely iptacopan works over the long term for people with C3G or IC-MPGN. You may be able to join if you already finished a specific earlier study and you’re currently healthy enough for long-term treatment.
Aurora, ColoradoAges 12–100 - NCT03854110RecruitingPhase 1
Testing a new drug for ovarian cancer that resists platinum chemo
This trial studies a new drug, misetionamide, given alone or with gemcitabine, for people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Chicago, IllinoisAges 18 years+ - NCT03838926RecruitingPhase 1
Testing how safe and tolerable a new drug is for blood cancers
This Phase 1 study tests how safe and tolerable trichostatin A is in adults whose blood cancers have come back or did not respond to standard treatments. It may help researchers find an effective dose while monitoring side effects closely.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.